Federal Circuit invalidates Sequenom patent, cites Mayo

A US appeals court has affirmed that a patent covering the method of detecting foetal abnormalities in pregnant mothers is ineligible for protection because it applies to a “natural phenomenon”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Ariosa says the sky is not falling, so Federal Circuit decision must stand

22 October 2015 Ariosa Diagnostics has urged the US Court of Appeals for the Federal Circuit to reject Sequenom’s en banc request, stating that behind its “sky is falling” rhetoric is really a demand for courts to revise the US Supreme Court’s two-part test in determining the eligibility of a patent.

Americas

Sequenom’s en banc bid boosted by support from US professors

2 September 2015 A group of 23 law professors has urged the US Court of Appeals for the Federal Circuit to re-hear the Ariosa v Sequenom dispute en banc.

Americas

CAFC must end ‘existential threat’ to patents, argues Sequenom

19 August 2015 Sequenom has requested an en banc review of the US Court of Appeals for the Federal Circuit’s decision to invalidate one of its patents in its dispute with Ariosa Diagnostics, arguing that the decision creates an “existential threat” to patent protection.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Federal Circuit invalidates Sequenom patent, cites Mayo

More on this story

Editor's picks

Editor's picks

More features